toceranib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
angiogenesis inhibitors 5634 356068-94-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • toceranib
  • PHA-291639
  • palladia
  • toceranib phosphate
A tyrosine kinase inhibitor
  • Molecular weight: 396.47
  • Formula: C22H25FN4O2
  • CLOGP: 2.58
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 77.23
  • ALOGS: -4.05
  • ROTB: 5

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.074 Moderate 0.78
caco2-efflux Caco-2 efflux ratio (BA/AB) 9.931 Moderate 0.78
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 7.129 10^-6 cm/s Moderate 0.78
dh-clint Dog hepatocyte intrinsic clearance 6.053 uL/min/10^6 cells Moderate 0.78
dppb Dog plasma protein binding (% unbound) 12.480 % Moderate 0.78
fcs-ppb Fetal calf serum protein binding (% unbound) 23.440 % Moderate 0.78
herg hERG pIC50 5.406 pIC50 Moderate 0.78
hh-clint Human hepatocyte intrinsic clearance 3.365 uL/min/10^6 cells Moderate 0.78
hlm-clint Human liver microsomal intrinsic clearance 14.191 uL/min/mg protein Moderate 0.78
hppb Human plasma protein binding (% unbound) 7.450 % Moderate 0.78
kinase-safety-class AAK1,ABL1,ABL2,ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,BTK,CAMK1,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK1,CDK14,CDK16,CDK19,CDK2,CDK3,CDK4,CDK5,CDK6,CDK7,CDK9,CHEK1,CHEK2,CHUK,CLK1,CLK2,CLK4,CSF1R,CSK,CSNK2A2,DDR1,DYRK1A,DYRK1B,DYRK2,DYRK3,EGFR,EIF2AK3,EPHA2,EPHB1,EPHB4,ERBB2,ERBB4,FGFR1,FGFR4,FLT1,FLT3,FLT4,FYN,GAK,GRK1,GRK2,GSK3A,GSK3B,HASPIN,HIPK2,IGF1R,IKBKB,INSR,IRAK1,IRAK3,IRAK4,ITK,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K19,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP3K9,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK12,MAPK15,MAPK3,MAPK7,MAPK8,MAPK9,MARK1,MARK2,MARK3,MARK4,MELK,MET,MINK1,MKNK1,MKNK2,MST1R,MTOR,MYLK,NTRK1,NTRK2,NTRK3,NUAK1,PAK1,PAK2,PAK4,PAK5,PDGFRB,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PLK1,PLK2,PLK3,PLK4,PRKAA1,PRKAA2,PRKACA,PRKCA,PRKCD,PRKCI,PRKCZ,PRKD1,PRKDC,PTK2,PTK6,RET,RIPK3,ROCK1,ROCK2,RPS6KA1,SGK1,SIK2,SIK3,SRC,STK10,STK16,STK17A,STK3,STK33,STK4,SYK,TBK1,TEK,TGFBR1,TNIK,TNK1,TTK,TYRO3,UHMK1,ULK1,ULK2,YES1,ZAP70 181
kinase-selectivity-class AAK1,ABL2,ACVR2A,ACVR2B,ALK,AURKA,AURKB,AURKC,AXL,BLK,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK9,CHEK1,CLK2,CLK4,CSF1R,CSK,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FGFR1,FLT1,FLT3,FLT4,FYN,GAK,GRK2,GSK3A,GSK3B,HASPIN,HIPK2,IGF1R,IKBKB,INSR,IRAK1,IRAK3,IRAK4,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP2K3,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K19,MAP3K2,MAP3K21,MAP3K7,MAP3K9,MAP4K1,MAP4K3,MAP4K5,MAPK1,MAPK12,MAPK7,MARK1,MARK2,MARK3,MARK4,MELK,MET,MINK1,MKNK2,MST1R,MTOR,NTRK1,NTRK3,NUAK1,PAK2,PAK4,PAK5,PDGFRB,PDK1,PDK4,PDPK1,PIK3CA,PIM3,PLK4,PRKAA1,PRKAA2,PRKCD,PRKCZ,PRKDC,PTK2,RET,ROCK1,SGK1,SIK2,SIK3,SRC,STK10,STK16,STK17A,STK33,STK4,SYK,TEK,TNIK,TNK1,TTK,TYRO3,ULK1,ULK2,YES1,ZAP70 128
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 7.464 Moderate 0.73
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 15.417 Moderate 0.78
mh-clint Mouse hepatocyte intrinsic clearance 28.774 Moderate 0.78
mppb Mouse plasma protein binding (% unbound) 8.200 Moderate 0.78
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 32.659 Moderate 0.78
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 Moderate 0.73
pppb Pig plasma protein binding (% unbound) 21.950 % Moderate 0.78
rat-kpuu-brain Rat brain Kpuu 0.042 % Moderate 0.73
rh-clint Rat hepatocyte intrinsic clearance 11.402 uL/min/10^6 cells Moderate 0.78
rh-fuinc Rat hepatocyte fraction unbound in incubation 44.330 % Moderate 0.78
rppb Rat plasma protein binding (% unbound) 9.520 % Moderate 0.78
solubility-dd Solubility at pH 7.4 in DMSO 233.884 uM Moderate 0.78

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement Indication

🐶 Veterinary products

ProductApplicantIngredients
Palladia Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Platelet-derived growth factor receptor beta Kinase IC50 9 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Ki 8.22 IUPHAR
Platelet-derived growth factor receptor alpha Kinase INHIBITOR Ki 8.30 IUPHAR
Fibroblast growth factor receptor 1 Kinase INHIBITOR Ki 6.30 IUPHAR
Serine/threonine-protein kinase tousled-like 2 Kinase IC50 5.60 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Ki 8.22 IUPHAR
Fibroblast growth factor receptor 1 Kinase INHIBITOR Ki 6.30 IUPHAR
Platelet-derived growth factor receptor alpha Kinase INHIBITOR Ki 8.30 IUPHAR

External reference:

IDSource
CHEBI:747974 CHEBI
CHEMBL13608 ChEMBL_ID
11619 IUPHAR_LIGAND_ID
449278009 SNOMEDCT_US
449541005 SNOMEDCT_US
768537000 SNOMEDCT_US
C2825368 UMLSCUI
BWC PDB_CHEM_ID
CHEMBL2103833 ChEMBL_ID
9069 INN_ID
874819-74-6 SECONDARY_CAS_RN
D08503 KEGG_DRUG
5329106 PUBCHEM_CID
017775 NDDF
017776 NDDF
59L7Y0530C UNII
1145944 RXNORM
C464577 MESH_SUPPLEMENTAL_RECORD_UI
59L7Y0530C INXIGHT DRUGS

Pharmaceutical products:

None